Literature DB >> 20138033

Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects.

Wenbao Huang1, Guoxian Zhu, Meixian Huang, Guoqiang Lou, Yi Liu, Shuying Wang.   

Abstract

BACKGROUND: The association between OPN level and the histological severity of hepatic fibrosis and inflammation in hepatitis C virus (HCV) induced liver fibrosis remains unknown.
METHODS: 120 chronic HCV-infected subjects and 75 controls were enrolled in this study. Assessment of liver histology was performed based on liver biopsy. Plasma OPN levels were determined.
RESULTS: Significant differences were noted in the mean plasma OPN levels between subjects with extensive fibrosis and those with mild fibrosis (4.29+/-1.01 ng/ml vs. 2.15+/-0.63 ng/ml, respectively; p<0.001). Similarly, the subjects with higher histological activity index (HAI) score had elevated OPN levels than those with mild HAI score (4.41+/-1.11 ng/ml vs. 2.25+/-0.94 ng/ml, respectively; p<0.001). The correlation between the plasma OPN levels and the severity of liver fibrosis degree and HAI score were noted (r=0.945, and r=0.788, respectively both p<0.001). Logistic regression analysis showed that serum OPN was an independent risk factor contributing to extensive liver fibrosis and inflammation (p=0.0018 and p<0.001, respectively) in patients with HCV subjects.
CONCLUSION: The plasma OPN level is correlated with the severity of liver fibrosis and inflammation, suggesting OPN could be used as a biomarker to evaluate the severity of liver damages in HCV subjects. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138033     DOI: 10.1016/j.cca.2010.01.029

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  27 in total

1.  Osteopontin contributes to TGF-β1 mediated hepatic stellate cell activation.

Authors:  Xiao Xiao; Yi Gang; Yong Gu; Lina Zhao; Jindong Chu; Jinfeng Zhou; Xiqiang Cai; Hui Zhang; Li Xu; Yongzhan Nie; Kaichun Wu; Zhiguo Liu; Daiming Fan
Journal:  Dig Dis Sci       Date:  2012-06-04       Impact factor: 3.199

2.  NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease.

Authors:  Wing-Kin Syn; Kolade M Agboola; Marzena Swiderska; Gregory A Michelotti; Evaggelia Liaskou; Herbert Pang; Guanhua Xie; George Philips; Isaac S Chan; Gamze F Karaca; Thiago de Almeida Pereira; Yuping Chen; Zhiyong Mi; Paul C Kuo; Steve S Choi; Cynthia D Guy; Manal F Abdelmalek; Anna Mae Diehl
Journal:  Gut       Date:  2012-03-17       Impact factor: 23.059

3.  Elevated serum osteopontin levels in chronic hepatitis C virus infection: association with autoimmune rheumatologic manifestations.

Authors:  Iman H Bassyouni; Rasha H Bassyouni; Nermin H Ibrahim; Ahmed F Soliman
Journal:  J Clin Immunol       Date:  2012-06-24       Impact factor: 8.317

4.  Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients.

Authors:  Yousri Mostafa Hussein; Ayman Alhazmi; Saad Alzahrani; Ahmad El-Askary; Abdulrahman Alghamdy; Eman Bayomy; Assmaa Selim; Mohammed Alghamdy
Journal:  Afr Health Sci       Date:  2017-06       Impact factor: 0.927

5.  Increased osteopontin and liver stiffness measurement by transient elastography in biliary atresia.

Authors:  Sittisak Honsawek; Maneerat Chayanupatkul; Voranush Chongsrisawat; Paisarn Vejchapipat; Yong Poovorawan
Journal:  World J Gastroenterol       Date:  2010-11-21       Impact factor: 5.742

6.  Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.

Authors:  Caralee J Schaefer; Karl Kossen; Sharlene R Lim; Jiing-Huey Lin; Lin Pan; Williamson Bradford; Patrick F Smith; Scott D Seiwert
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

7.  Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.

Authors:  Radan Bruha; Marie Jachymova; Jaromir Petrtyl; Karel Dvorak; Martin Lenicek; Petr Urbanek; Tomislav Svestka; Libor Vitek
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

8.  Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.

Authors:  Wing-Kin Syn; Steve S Choi; Evaggelia Liaskou; Gamze F Karaca; Kolade M Agboola; Ye Htun Oo; Zhiyong Mi; Thiago A Pereira; Marzena Zdanowicz; Padmini Malladi; Yuping Chen; Cynthia Moylan; Youngmi Jung; Syamal D Bhattacharya; Vanessa Teaberry; Alessia Omenetti; Manal F Abdelmalek; Cynthia D Guy; David H Adams; Paul C Kuo; Gregory A Michelotti; Peter F Whitington; Anna Mae Diehl
Journal:  Hepatology       Date:  2010-10-21       Impact factor: 17.425

Review 9.  Osteopontin and Transplantation: Where Are We Now?

Authors:  Beata Kaleta
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-05-21       Impact factor: 4.291

10.  Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans.

Authors:  James Pritchett; Emma Harvey; Varinder Athwal; Andrew Berry; Cliff Rowe; Fiona Oakley; Anna Moles; Derek A Mann; Nicoletta Bobola; Andrew D Sharrocks; Brian J Thomson; Abed M Zaitoun; William L Irving; Indra N Guha; Neil A Hanley; Karen Piper Hanley
Journal:  Hepatology       Date:  2012-09       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.